{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T10:57:31Z","timestamp":1742381851337},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OTT"],"DOI":"10.2147\/ott.s83952","type":"journal-article","created":{"date-parts":[[2015,5,18]],"date-time":"2015-05-18T22:40:46Z","timestamp":1431988846000},"page":"1111","source":"Crossref","is-referenced-by-count":8,"title":["Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)"],"prefix":"10.2147","author":[{"given":"Mitsukuni","family":"Suenaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Matsusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Akiyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Oya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Mizunuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiharu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,5]]},"container-title":["OncoTargets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=25100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T18:35:47Z","timestamp":1477852547000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/perioperative-folfox4-plus-bevacizumab-for-initially-unresectable-adva-peer-reviewed-article-OTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/ott.s83952","relation":{},"ISSN":["1178-6930"],"issn-type":[{"value":"1178-6930","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}